Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Summary

This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease Inhibitor (PI) based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg BID.

Timeline

Start

2009-05

Primary completion

2013-05

Completion

2013-11

Drugs

Indications